PerkinElmer – Consensus Says Potential of -7.6% Down


PerkinElmer found using a stock ticker (PKI) now have 14 analysts covering the stock with the consensus suggesting a rating of “Buy”. The target price varies between 193 and 135 by calculating the average target price that we have 161.21. With the stock’s previous close at 174.46, this indicates that there is a potential decline of -7.6%. The 50 day MA is 155.03 and the 200 moving average is now rising to 141.55. The market capitalization of the company is $ 20,098 million. Company website: http://www.perkinelmer.com

PerkinElmer provides products, services and solutions to the diagnostic, life science and applied services markets around the world. The company operates in two segments, discovery and analysis solutions and diagnostics. The Discovery & Analytical Solutions segment offers a suite of solutions including reagents, computing, and detection and imaging technologies that enable scientists to enhance research advancements in the science research market. life, as well as laboratory services. It also provides technologies, solutions and analytical services for the environmental, food and industrial markets that enable its clients to understand the characterization and health of various aspects, including air, water and soil. In addition, this segment offers solutions to farmers and food producers; and analytical instrumentation for the industrial market, which includes the chemicals, semiconductors and electronics, energy, lubricants, petrochemicals and polymers sectors. The Diagnostics segment provides instruments, reagents, assay platforms and software products for the early detection of genetic disorders, such as pregnancy and infancy, as well as the screening of infectious diseases in the diagnostics market. Its products are used to test and screen for genetic abnormalities, disorders and diseases, including Down syndrome, hypothyroidism, muscular dystrophy, infertility and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein-coupled receptors and next-generation DNA sequencing for oncology and drug discovery applications. The company serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private health organizations, physicians and government agencies. PerkinElmer was founded in 1937 and is headquartered in Waltham, Massachusetts.

You can now share this on Stocktwits, just click on the logo below and add the ticker in the text to be seen.


Comments are closed.